Cargando…

Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received

SIMPLE SUMMARY: Hodgkin lymphoma (HL) is considered a largely curable disease (~80%). The young patient age at diagnosis and their long life expectancy make quality-of-life issues, including osteopenia, exceedingly important. This study aimed to assess treatment-related bone mineral density (BMD) ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ofshenko, Nadav, Bercovich, Eyal, Mashiach, Tania, Weiler-Sagie, Michal, Militianu, Daniela, Dann, Eldad J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833719/ https://www.ncbi.nlm.nih.gov/pubmed/35158763 http://dx.doi.org/10.3390/cancers14030495

Ejemplares similares

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Advanced Hodgkin Lymphoma: a New Era of Therapy
por: Dann, Eldad J.
Publicado: (2014)

Hodgkin Disease—An Ever-Evolving Therapy
por: Dann, Eldad J.
Publicado: (2014)

P1072: SIGNIFICANT PREDICTORS OF DECREASED BONE MINERAL DENSITY IN PATIENTS WITH HODGKIN’S LYMPHOMA
por: Voytko, Mariya, et al.
Publicado: (2023)

Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures
por: Bodden, J., et al.
Publicado: (2020)

P1078: PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMORAL SEROLOGICAL RESPONSE TO VACCINATION WITH TWO DOSES OF BNT162B2 AND THEIR IGG ANTIBODY LEVELS MARKEDLY INCREASE AFTER A THIRD VACCINE DOSE
por: Dann, E., et al.
Publicado: (2022)

The Legacy of Thomas Hodgkin Is Still Relevant 150 Years After His Death. Nothing of Humanity Was Foreign to Him
por: Dann, Eldad J.
Publicado: (2017)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
por: Anargyrou, Konstantinos, et al.
Publicado: (2019)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014)

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
por: Castagna, Luca, et al.
Publicado: (2020)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
por: Hatam, Nahid, et al.
Publicado: (2015)

Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.
por: Holmes, S. J., et al.
Publicado: (1994)

Comparison of vertebral and femoral bone mineral density in adult females
por: Choe, Han Seong, et al.
Publicado: (2016)

Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Lee, Jae Min, et al.
Publicado: (2013)

Evaluation of Bone Mineral Density in Children with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL): Chemotherapy with/without Radiotherapy
por: Ghassemi, Ali, et al.
Publicado: (2016)

Angiogenesis in Non-Hodgkin's Lymphoma: An Intercategory Comparison of Microvessel Density
por: Aggarwal, Deepti, et al.
Publicado: (2012)

Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens.
por: Ingram, L., et al.
Publicado: (1987)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy
por: Jayabose, Somasundaram, et al.
Publicado: (2016)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

Hodgkin's lymphoma masquerading as vertebral osteomyelitis in a man with diabetes: a case report
por: Bender Ignacio, Rachel A, et al.
Publicado: (2010)

P1076: PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS
por: Dann, Eldad, et al.
Publicado: (2023)

Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2014)

Correction: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo, Luca, et al.
Publicado: (2021)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

Evaluation of vertebral bone mineral density in scoliosis by using quantitative computed tomography
por: Sarioglu, Orkun, et al.
Publicado: (2019)

Impact of Bone Mineral Density on the Incidence of Age-Related Vertebral Fragility Fracture
por: Lee, Jeongik, et al.
Publicado: (2020)

Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
por: Pezzaioli, L. C., et al.
Publicado: (2021)

Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
por: Cunha Pereira, Tatiana, et al.
Publicado: (2020)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients
por: Prayogo, Ami Ashariati, et al.
Publicado: (2022)

Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen
por: Morgan, Judah D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l285b2a3dh9r5925jstpmd6qvp